The 2nd Korea-Japan Bio Ecosystem Roundtable took place in Tokyo, uniting Korean biotech firms and Japanese pharmaceutical giants to strengthen collaboration and strategize for global expansion.
Designed to deepen biotech cooperation between Korea and Japan, the roundtable provided a platform for in-depth discussions on potential partnerships and technological advancements.
Backed by the South Korean government, six leading Korean biotech companies joined the event, engaging with top Japanese pharmaceutical firms, including Takeda Pharmaceutical, Astellas Pharma, Sumitomo Pharma, and Mitsubishi Tanabe Pharma.
As cross-border collaboration gains momentum, the event underscored opportunities for co-development, technology exchange, and investment in the fast-evolving biotech sector. Experts predict that such initiatives will drive innovation and enhance the global competitiveness of companies from both nations.
Participating Korean bio ventures
- CEFO= Focuses on research and development of stem cell therapies.
- EDGENE= Develops gene editing platforms and solutions for rare diseases.
- TXINOBIOSCIENCE= Specializes in innovative anti-cancer small molecules and targeted protein degraders.
- Raphas=Produces and sells biodegradable microneedle patches for cosmetic and medical applications.
- BIOLOGICS= Advances immuno-oncology antibody development using its proprietary human antibody library, Ymax®-ABL, and bispecific antibody platform, ALiCE.
- CTCELLS= Develops personalized cancer diagnostics and therapeutics based on circulating tumor cell (CTC) liquid biopsy technology.
